Skip to main content

Table 2 Preprandial plasma glucose levels

From: Risk of hypoglycemia associated with repaglinide combined with clopidogrel, a retrospective cohort study

Preprandial plasma glucoseRepaglinide and clopidogrel groupMitiglinide and clopidogrel groupRepaglinide group
(N = 15)(N = 15)(N = 15)
Breakfast
 Before starting glinide180.1 ± 35.5161.8 ± 38.0151.0 ± 20.9
 After starting glinide136.5 ± 44.1150.1 ± 41.3127.8 ± 33.0
 Decrease in the amplitude of glycemic excursions43.6 ± 33.6 *11.6 ± 30.023.2 ± 23.7
Lunch
 Before starting glinide228.2 ± 48.6231.7 ± 48.7196.1 ± 32.3
 After starting glinide178.8 ± 69.8177.2 ± 53.9168.7 ± 37.2
 Decrease in the amplitude of glycemic excursions50.0 ± 36.655.8 ± 43.327.4 ± 38.9
Dinner
 Before starting glinide193.3 ± 54.5190.5 ± 47.6186.8 ± 56.5
 After starting glinide131.6 ± 43.4165.9 ± 44.6144.3 ± 52.8
 Decrease in the amplitude of glycemic excursions61.6 ± 49.324.6 ± 45.042.5 ± 38.9
  1. Mean ± S.D., * p < 0.05 for the “repaglinide and clopidogrel group” versus the “mitiglinide and clopidogrel group”